TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05983523: A Phase I Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors

Sponsor: PharmaEngine · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,613,296

Rescue Site Savings

+$6,346,032

Unlock Full NCT05983523 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05983523 Rescue Dossier →